TOLREMO therapeutics

TOLREMO therapeutics mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit

Drug discovery,drug development,cancer drug resistance,non-genetic cancer drug resistance,and biotech

Tolremo therapeutics operates in the Biotechnology research industry.

Tolremo therapeutics's revenue is 11m - 100m

Tolremo therapeutics has 11 - 50 employees.